1.66
price up icon0.61%   0.01
 
loading
Prokidney Corp stock is traded at $1.66, with a volume of 15,719. It is up +0.61% in the last 24 hours and down -11.23% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
See More
Previous Close:
$1.65
Open:
$1.66
24h Volume:
15,719
Relative Volume:
0.02
Market Cap:
$213.48M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.1005
EPS:
-0.5354
Net Cash Flow:
$-124.27M
1W Performance:
-22.79%
1M Performance:
-11.23%
6M Performance:
-55.14%
1Y Performance:
-10.75%
1-Day Range:
Value
$1.65
$1.66
1-Week Range:
Value
$1.50
$2.18
52-Week Range:
Value
$1.18
$4.44

Prokidney Corp Stock (PROK) Company Profile

Name
Name
Prokidney Corp
Name
Phone
336-999-7028
Name
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Name
Employee
163
Name
Twitter
Name
Next Earnings Date
2024-12-09
Name
Latest SEC Filings
Name
PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PROK 1.66 213.48M 0 -35.47M -124.27M -0.5354
VRTX 447.51 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.12 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.75 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.52 24.49B 3.30B -501.07M 1.03B 11.54

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-21-22 Initiated Jefferies Buy
Nov-10-22 Initiated Morgan Stanley Equal-Weight
Oct-18-22 Initiated UBS Buy
Oct-14-22 Initiated Citigroup Buy
Sep-23-22 Initiated BofA Securities Buy
Sep-02-22 Initiated Evercore ISI Outperform
View All

Prokidney Corp Stock (PROK) Latest News

pulisher
Nov 20, 2024

ProKidney no longer coming to Greensboro, Chamber of Commerce confirms - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

ProKidney puts is Greensboro factory site up for sale - Winston-Salem Journal

Nov 19, 2024
pulisher
Nov 19, 2024

ProKidney: Manufacturing expansion moving to W-S instead of Greensboro - Triad Business Journal

Nov 19, 2024
pulisher
Nov 18, 2024

ProKidney lists Greensboro property for sale, leaving future in city uncertain - WFMYNews2.com

Nov 18, 2024
pulisher
Nov 18, 2024

ProKidney lists building where it planned $458M investment for sale - The Business Journals

Nov 18, 2024
pulisher
Nov 18, 2024

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely - Simply Wall St

Nov 18, 2024
pulisher
Nov 12, 2024

ProKidney’s Progress in FDA Approval and Financial Health - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

ProKidney Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

ProKidney Surges on FDA Backing for Phase 3 Study, Reports $406.8M Cash Position | PROK Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Triad's public companies have gained millions in value since election - Triad Business Journal

Nov 11, 2024
pulisher
Nov 08, 2024

Morgan Stanley's Strategic Reduction in ProKidney Corp Holdings - GuruFocus.com

Nov 08, 2024
pulisher
Nov 07, 2024

ProKidney: Major Catalyst Is Too Far Away (NASDAQ:PROK) - Seeking Alpha

Nov 07, 2024
pulisher
Nov 06, 2024

ProKidney to Participate in the Guggenheim Inaugural - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

ProKidney (PROK) to Present at Guggenheim and Jefferies Healthcare Conferences | PROK Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

ProKidney amends Phase III protocol in light of Phase II results - MSN

Nov 04, 2024
pulisher
Oct 26, 2024

Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World

Oct 26, 2024
pulisher
Oct 23, 2024

ProKidney CEO Bruce Culleton named to Triad Power 50 Five to Watch list - The Business Journals

Oct 23, 2024
pulisher
Oct 22, 2024

Suvretta Capital Management's Strategic Acquisition in ProKidney Corp - Yahoo Finance

Oct 22, 2024
pulisher
Oct 21, 2024

Reviewing ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) - Defense World

Oct 21, 2024
pulisher
Oct 18, 2024

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate - Yahoo Finance

Oct 18, 2024
pulisher
Oct 14, 2024

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - The Manila Times

Oct 14, 2024
pulisher
Oct 14, 2024

ProKidney Announces Five Abstracts Selected for - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024 - Yahoo Finance

Oct 14, 2024
pulisher
Oct 11, 2024

Stocks of ProKidney Corp (PROK) are poised to climb above their peers - SETE News

Oct 11, 2024
pulisher
Oct 11, 2024

Gaining Ground: ProKidney Corp (PROK) Closes Lower at 1.70, Down -0.58 - The Dwinnex

Oct 11, 2024
pulisher
Oct 10, 2024

PROK underperforms with a -1.16 decrease in share price - US Post News

Oct 10, 2024
pulisher
Oct 09, 2024

ProKidney Corp (PROK) Becoming More Attractive for Investors - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

PROK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewswire

Oct 09, 2024
pulisher
Oct 03, 2024

ProKidney Corp [PROK] Records 50-Day SMA of $2.2292 - Knox Daily

Oct 03, 2024
pulisher
Oct 02, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

ProKidney Corp (PROK) deserves deeper analysis - US Post News

Oct 01, 2024
pulisher
Sep 30, 2024

Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

JPMorgan Chase & Co. Initiates Coverage on ProKidney (NASDAQ:PROK) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle

Sep 30, 2024
pulisher
Sep 30, 2024

ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com

Sep 30, 2024
pulisher
Sep 27, 2024

How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News

Sep 27, 2024
pulisher
Sep 26, 2024

Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St

Sep 26, 2024
pulisher
Sep 24, 2024

ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex

Sep 23, 2024
pulisher
Sep 21, 2024

ProKidney revises Phase 3 program for lead asset - MSN

Sep 21, 2024
pulisher
Sep 21, 2024

Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia

Sep 21, 2024
pulisher
Sep 20, 2024

ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat

Sep 20, 2024

Prokidney Corp Stock (PROK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):